Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.8K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.1K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023.

Hepatology international·2026
Same author

Systematic benchmarking of CUT&Tag improves the reliability and reproducibility of chromatin analysis.

Cell reports methods·2026
Same author

PARP1 modulates BBB function via regulating NLRC5 in cerebral endothelial cells during ischemic stroke.

Experimental neurology·2026
Same author

Harnessing artificial intelligence for pediatric health: Current trends and future opportunities.

iScience·2026
Same author

Protein yogurt and whey protein produce comparable muscle gains, but divergent microbiome shifts during strength training in older adults.

Scientific reports·2026
Same author

YAP1 signaling and cancer: molecular pathways reveal novel targeting opportunities.

Expert opinion on therapeutic targets·2026

Related Experiment Video

Updated: Nov 7, 2025

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.0K

Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and

Tatiana R Perry1, Michelle L Roberts2,3,4, Bipin Sunkara5

  • 1Medical College of Wisconsin, Milwaukee, WI, USA.

Current Oncology Reports
|May 3, 2021
PubMed
Summary
This summary is machine-generated.

Human-induced pluripotent stem cells (hiPSCs) offer a new way to study cancer therapy

Keywords:
Cardio-oncologyCardiovascular toxicityPrecision medicinePreventionRisk stratificationhiPSCs

More Related Videos

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
10:30

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

3.1K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K

Related Experiment Videos

Last Updated: Nov 7, 2025

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.0K
Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
10:30

Technical Applications of Microelectrode Array and Patch Clamp Recordings on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Published on: August 4, 2022

3.1K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.1K

Area of Science:

  • Cardio-oncology
  • Stem cell research
  • Cardiovascular toxicology

Background:

  • Cardiovascular toxicity is a major concern for cancer survivors.
  • Cancer therapies like anthracyclines, HER2 antibodies, and TKIs can harm the heart.
  • Precision cardio-oncology aims to personalize treatment to prevent heart damage.

Purpose of the Study:

  • To review how human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are used to study cancer therapy cardiotoxicity.
  • To explore the role of hiPSC models in advancing precision cardio-oncology.
  • To identify future directions for using hiPSCs in personalized cardio-oncology.

Main Methods:

  • Evaluation of common cancer therapeutic agents in hiPSC-derived cardiomyocytes.
  • Synthesis of evidence on mechanisms of cardiovascular toxicity.
  • Analysis of hiPSC modeling in relation to patient comorbidities and risk factors.

Main Results:

  • hiPSC-CMs enable the study of cardiotoxicity mechanisms and pharmacological discovery.
  • Patients with comorbidities show increased adverse responses in hiPSC studies.
  • hiPSC modeling can help predict individual susceptibility to cardiotoxicity.

Conclusions:

  • hiPSC technology is crucial for understanding and predicting cardiotoxicity.
  • Personalized models using hiPSCs can lead to tailored cancer treatment plans.
  • Multidisciplinary collaboration is key for implementing hiPSCs in clinical cardio-oncology.